目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Therapy
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Gane Therapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. High growth of the pharmaceutical industry
3.2.1.2. Rising R&D investments and demand for novel cancer therapeutics
3.2.1.3. Increased incidence of cancers
3.2.2. Market Restraint Analysis
3.2.2.1. High product prices
3.2.2.2. Unethical use of gene therapy
3.3. Cancer Gene Therapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gane Therapy Market: Therapy Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Cancer Gene Therapy Market: Therapy Movement Analysis
4.3. Cancer Gene Therapy Market by Therapy Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Oncolytic Virotherapy
4.5.1. Oncolytic Virotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Gene Induced Immunotherapy
4.6.1. Gene Induced Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Gene Transfer
4.7.1. Gene Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: End Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Cancer Gene Therapy Market: End Use Movement Analysis
5.3. Cancer Gene Therapy Market by End Use Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Research Institutes
5.5.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Biopharmaceutical Companies
5.6.1. Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Diagnostic Centers
5.7.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Therapy and End Use
6.1. Regional Dashboard
6.2. Regional Cancer Gene Therapy Market Movement Analysis
6.3. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Technology & End Use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
6.5.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. U.S.
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement scenario
6.5.2.5. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Canada
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement scenario
6.5.3.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement scenario
6.5.4.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Europe
6.6.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. UK
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement scenario
6.6.2.5. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Germany
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement scenario
6.6.3.5. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. Switzerland
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement scenario
6.6.4.5. Switzerland Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Japan
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement scenario
6.7.2.5. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. China
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement scenario
6.7.3.5. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. Reimbursement scenario
6.7.4.5. Australia Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Rest of World
6.8.1. Latin America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Abeona Therapeutics Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Asklepios BioPharmaceutical Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Altor Bioscience Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Bluebird bio Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. BioCancell Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. CelgeneInc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Elevate BioInc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. GlaxoSmithKlineInc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Genelux Corporation
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. GenVec
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Introgen TherapeuticsInc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. OncoGenex Pharmaceuticals Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 4 Global cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America cancer gene therapy market, by region, 2018 - 2030 (USD Million)
Table 6 North America cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 7 North America cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 8 U.S. cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 9 U.S. cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 10 Canada cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 11 Canada cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 12 Mexico cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 13 Mexico cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 14 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 15 Europe cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 16 Europe cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 17 UK cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 18 UK cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 19 Germany cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 20 Germany cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 21 Switzerland cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 22 Switzerland cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 23 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 24 Asia Pacific cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 25 Asia Pacific cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 26 Japan cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 27 Japan cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 28 China cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 29 China cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 30 Australia cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 31 Australia cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 32 Rest of World cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 33 Rest of World cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Information Procurement Primary Research Pattern
Fig. 2 Market Research Approaches
Fig. 3 Value Chain-Based Sizing & Forecasting
Fig. 4 Market Formulation & Validation
Fig. 5 Market driver analysis
Fig. 6 Market restraint analysis
Fig. 7 PESTEL Analysis
Fig. 8 Porter’s Five Forces Analysis
Fig. 9 Cancer gene therapy market, therapy outlook key takeaways (USD Million)
Fig. 10 Cancer gene therapy market: Therapy movement analysis 2023 & 2030 (USD Million)
Fig. 11 Oncolytic Virotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 12 Gene induced immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 13 Gene transfer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Cancer gene therapy market, end use outlook key takeaways (USD Million)
Fig. 15 Cancer gene therapy market: End use movement analysis (USD Million), 2023 & 2030
Fig. 16 Research institutes market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Biopharmaceutical companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Diagnostic centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Cancer gene therapy market: Regional key takeaways (USD Million)
Fig. 21 Cancer gene therapy market: regional outlook, 2023 & 2030 (USD Million)
Fig. 22 North America cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 U.S. cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Canada cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Mexico cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Europe cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 UK cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Germany cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Switzerland cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Asia Pacific cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 China cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Japan cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Australia cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Rest of World cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)